|
|
|
|
XOMA Plunges on $21M Offering; Is Diabetes Drug Partner Near?
Shares of XOMA Ltd.fell 34.5 percent on Tuesday after the company announced a $21 million registered direct offering of stock and warrants. XOMA sold 42 million units for 50 cents apiece, with each unit consisting of one common share and one five-year...
|
|
|
Psoriasis - Biologics Make $1.4 Billion Of Sales
New report provides detailed analysis of the Healthcare and Medical market Published on January 22, 2010by Press Office(Companiesandmarkets.com and OfficialWire)LONDON, ENGLAND The launch of new brands in both biologic and topical treatments in 2009 is shaking...
|
|
|
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
- Focus Will Be on Establishing Investigator-Sponsored Trials Program to Expand Bavituximab Clinical Development Efforts - - Brings Extensive Experience in the Design and Conduct of Clinical Trials for Innovative Therapies for Cancer and Other Indications -...
|
|
|
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
- Focus Will Be on Establishing Investigator-Sponsored Trials Program to Expand Bavituximab Clinical Development Efforts - - Brings Extensive Experience in the Design and Conduct of Clinical Trials for Innovative Therapies for Cancer and Other Indications -...
|
|
|
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
Clinical Trials Update Breaking News PRNEWSWIRE TUSTIN, Calif., Jan.11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq:<em>PPHM) today announced that Marvin R. Garovoy, MD, has joined the company as head of clinical...
|
|
|
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
TUSTIN, Calif., Jan.11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that Marvin R. Garovoy, MD, has joined the company as head of clinical science. Garovoy has extensive biotechnology industry experience in...
|
|
|
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
- Focus Will Be on Establishing Investigator-Sponsored Trials Program to Expand Bavituximab Clinical Development Efforts - - Brings Extensive Experience in the Design and Conduct of Clinical Trials for Innovative Therapies for Cancer and Other Indications -...
|
|
|
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
TUSTIN, Calif., Jan.11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that Marvin R. Garovoy, MD, has joined the company as head of clinical science. Garovoy has extensive biotechnology industry experience in...
|
|
|
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
TUSTIN, Calif., Jan.11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that Marvin R. Garovoy, MD, has joined the company as head of clinical science. Garovoy has extensive biotechnology industry experience in...
|
|
|
Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent S
Managed Care Obstacles, Interest and Anticipated Use of Centocor Search News Releases WordPress Blog URL: Other News Releases in Other News Releases in Journalists and Bloggers Visit for releases, photos, experts, and customized feeds just for Media.View and...
|
|
|
Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent S
EXTON, Pa., Nov.25 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product...
|
